Kato M, Asaka M, Sugiyama T, Kudo M, Nishikawa K, Sukegawa M, Hokari K, Katagiri M, Sato F, Kagaya H, Takeda H
Third Department of Internal Medicine, Hokkaido University School of Medicine, Sapporo, Japan.
Dig Dis Sci. 1998 Sep;43(9 Suppl):198S-202S.
The aim of this study was to compare the additive effect of rebamipide with that of teprenone in combination with dual therapy on H. pylori eradication. A total of 102 H. pylori-positive gastric ulcer patients were assigned at random to two groups; in addition to dual therapy (amoxicillin 500 mg thrice daily and lansoprazole 30 mg every morning for two weeks), one group received rebamipide 100 mg thrice daily for eight weeks, while the other group received teprenone 50 mg thrice daily for eight weeks. H. pylori diagnosis after treatment was made by [13C]UBT. The ulcer healing rate was 85.7% in the rebamipide group and 79.5% in the teprenone group (P = NS). The eradication rate was 68.4% (95% CI = 54-83%) in the rebamipide group and 47.7% (95% CI = 32-61%) in the teprenone group (P = 0.043) by per-protocol analysis. These findings suggest that the efficacy of dual therapy may be increased by the administration of rebamipide.
本研究旨在比较瑞巴派特与替普瑞酮联合双重疗法对幽门螺杆菌根除的附加效果。总共102例幽门螺杆菌阳性胃溃疡患者被随机分为两组；除双重疗法（阿莫西林500毫克，每日三次，兰索拉唑30毫克，每天早晨服用，持续两周）外，一组接受瑞巴派特100毫克，每日三次，共八周，而另一组接受替普瑞酮50毫克，每日三次，共八周。治疗后通过[13C]尿素呼气试验进行幽门螺杆菌诊断。瑞巴派特组溃疡愈合率为85.7%，替普瑞酮组为79.5%（P=无显著性差异）。根据符合方案分析，瑞巴派特组根除率为68.4%（95%可信区间=54-83%），替普瑞酮组为47.7%（95%可信区间=32-61%）（P=0.043）。这些发现表明，给予瑞巴派特可能会提高双重疗法的疗效。
